Product Name: CDK1 (164-172) pT166+pY169
Product Number: PE-04ASG01
| Size: | 200 µg | Price: | 15.00 | |
| 1 mg | $US | 30.00 |
Peptide Name: CDK1 (164-172) pT166+pY169
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T166 and Y169 phosphorylations are predicted to be inhibitory.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VV-pT-LW-pY-RSP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T166 and Y169 phosphorylations are predicted to be inhibitory.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VV-pT-LW-pY-RSP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Purity Percent after Synthesis and Purification: crude
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: CDK1 (CDC2) is a protein-serine/threonine kinase of the CMGC group and CDK family. It plays an essential role in cell cycle control in eukaryotic cells by regulating the centrosome cycle, mitotic onset, G2-M phase transition, G1 progression, and G1-S phase transition through an association with various interphase cyclin proteins. Phosphorylation events at T14 or Y15 on the protein are inactivating, while phosphorylation at T161 is stimulatory. CDK1 appears to be a tumour requiring protein (TRP). Gain-of-function mutations in the CDK1 gene have been linked to several forms of cancer, indicating an oncogenic role for the CDK1 protein. Cells transformed with the oncogene MYC undergo apoptosis when treated with small-molecule CDK1 inhibitors. Elevated expression of CDK1 has been reported as a diagnostic marker for cancer progression in esophageal adenocarcinoma, potentially reflecting the role of the CDK1 protein in tumourigenesis. CDK1 expression can be used as a prognostic indicator for early breast cancer. For example, breast cancer tumours with high expression of CDK1 are correlated with a significantly lower 5-year patient survival rate (66. 9%) than tumours that have low levels of CDK1 expression (84. 2%).
© Kinexus Bioinformatics Corporation 2017